In a recent review of antiretroviral use in the Swiss Cohort, Atripla was the most frequent regimen used (28%).
The most common regimens were carboplatin (CBDCA) plus paclitaxel, and cisplatin (CDDP) plus S-1 (46 patients each), and the third most frequent regimen was CDDP plus vinorelbine (VNR) (41 patients).
Since the long-term visual outcomes of PDT were not good owing to the high frequency of recurrent polypoidal lesions resulting from residual BVNs, 13 17 the limitations of an as-needed reinjection schedule require further observations, and a future study comparing as-needed therapy to a more frequent regimen, such as an injection every two or three months, or treat and extend is warranted.
Most patients (68.8%) were receiving CT with palliative intent, with taxane monotherapy (15.9%) and gemcitabine monotherapy (10.5%) being the most frequent regimens.
Monthly or less frequent regimens lessen lifestyle disruption, preference assessments identify the attributes patients value, and bone turnover markers provide physiologic accountability.
The most frequent regimens among these patients included only a single drug, usually ampicillin-clavulanate (47 patients, 42%), doxycycline (27, 24%), and ceftriaxone (6, 5%).
Most frequent regimens were beta-lactam plus fluoroquinolones (n = 20, 62.5%); beta-lactam plus macrolides (n = 6; 18.7%) and beta-lactam plus linezolid (n = 5, 15.6%).
RTX retreatment is generally recommended at around six months based on clinical evaluation [ 3], whereas other RA biologicals are administered using monthly or more frequent regimens.
In Australia, nephrologists believed that medical and nursing expertise in home dialysis was good, that home HD was available and supported by most units, and that longer hours and/or more frequent regimens offered outcome advantages [ 37].
The most frequent regimens were fluoroquinolones plus β-lactam (n = 217, 63%), β-lactam plus macrolide (n = 73, 21%), fluoroquinolone monotherapy (n = 39, 11%) and β-lactam monotherapy (n = 18, 5%).
Basic demographic and clinical characteristics of the breast cancer patients are presented for the two most frequent chemotherapy regimens, and all regimens.
